Positive News SentimentPositive NewsNASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $178.13 -2.87 (-1.59%) Closing price 04:00 PM EasternExtended Trading$178.12 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Krystal Biotech Stock (NASDAQ:KRYS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$169.98▼$179.3850-Day Range$149.92▼$194.4452-Week Range$141.72▼$219.34Volume654,120 shsAverage Volume291,025 shsMarket Capitalization$5.13 billionP/E Ratio59.58Dividend YieldN/APrice Target$220.00Consensus RatingBuy Company OverviewKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More… Remove Ads Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 91% of companies evaluated by MarketBeat, and ranked 64th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth64.17% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 64.17% in the coming year, from $6.14 to $10.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 59.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 59.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.94.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.93% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 2.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.87 Percentage of Shares Shorted10.93% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 2.17%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment1.72 News SentimentKrystal Biotech has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Krystal Biotech this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 2 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,576,165.00 in company stock.Percentage Held by Insiders14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Stock News HeadlinesStocks Showing Improving Market Leadership: Metsera Earns 82 RS RatingMarch 24, 2025 | msn.comHarrow Shows Market Leadership With Jump To 92 RS RatingMarch 19, 2025 | msn.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 3, 2025 | Weiss Ratings (Ad)William Blair Sticks to Their Hold Rating for Legend Biotech (LEGN)March 12, 2025 | markets.businessinsider.comKrystal Biotech at TD Cowen Conference: Strategic Pipeline ProgressMarch 8, 2025 | uk.investing.comJefferies Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationMarch 5, 2025 | msn.comKrystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery techMarch 5, 2025 | msn.comKrystal Biotech initiated with a Buy at JefferiesMarch 5, 2025 | markets.businessinsider.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $156.66 at the beginning of 2025. Since then, KRYS shares have increased by 13.7% and is now trading at $178.13. View the best growth stocks for 2025 here. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Monday, February, 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. The business's revenue for the quarter was up 116.4% on a year-over-year basis. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings2/24/2025Today4/03/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Stock Price Target$220.00 High Stock Price Target$245.00 Low Stock Price Target$206.00 Potential Upside/Downside+24.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.99 Trailing P/E Ratio59.08 Forward P/E Ratio28.68 P/E GrowthN/ANet Income$10.93 million Net Margins30.69% Pretax Margin32.82% Return on Equity11.41% Return on Assets10.40% Debt Debt-to-Equity RatioN/A Current Ratio7.28 Quick Ratio7.76 Sales & Book Value Annual Sales$290.52 million Price / Sales17.46 Cash Flow$4.47 per share Price / Cash Flow39.38 Book Value$32.85 per share Price / Book5.36Miscellaneous Outstanding Shares28,806,000Free Float24,706,000Market Cap$5.07 billion OptionableOptionable Beta0.75 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:KRYS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.